Recurrent Glioblastoma Multiforme (GBM) Treatment Market Report

Global and Region Recurrent Glioblastoma Multiforme (GBM) Treatment Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Jul 30, 2022
  • PAGES：210
  • REPORT CODE：GMM896885
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The report details the trend, potential and market size of Recurrent Glioblastoma Multiforme (GBM) Treatment market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Recurrent Glioblastoma Multiforme (GBM) Treatmentmarket, defines the market attractiveness level of Recurrent Glioblastoma Multiforme (GBM) Treatment market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Recurrent Glioblastoma Multiforme (GBM) Treatment industry, describes the types of Recurrent Glioblastoma Multiforme (GBM) Treatment market, the applications of major players and the market size, and deeply analyzes the current situation of the global Recurrent Glioblastoma Multiforme (GBM) Treatment market and the development prospects and opportunities of Recurrent Glioblastoma Multiforme (GBM) Treatment industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Recurrent Glioblastoma Multiforme (GBM) Treatment market in Chapter 13.

    By Player:

    • AngioChem

    • GlaxoSmithKline

    • Roche

    • Vascular Biogeneics

    • Astrazeneca

    • Merck

    • Pfizer

    By Type:

    • Oral Medications

    • Temozolomide

    • Radiosensitizers

    • Nitrosoureas Drugs

    • Radiation Therapy

    • Chemotherapy

    By End-User:

    • Hospitals

    • Clinics

    • Ambulatory Surgical Centers

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Recurrent Glioblastoma Multiforme (GBM) Treatment Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Recurrent Glioblastoma Multiforme (GBM) Treatment Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Recurrent Glioblastoma Multiforme (GBM) Treatment Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Recurrent Glioblastoma Multiforme (GBM) Treatment Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Recurrent Glioblastoma Multiforme (GBM) Treatment Market Analysis and Outlook to 2022

    • 7.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

    • 7.2 United States Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

    • 7.3 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

    • 7.4 China Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

    • 7.5 Japan Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

    • 7.6 India Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

    • 7.7 South Korea Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption (2017-2022)

    8 Region and Country-wise Recurrent Glioblastoma Multiforme (GBM) Treatment Market Analysis and Outlook to 2028

    • 8.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

    • 8.2 United States Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

    • 8.3 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

    • 8.4 China Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

    • 8.5 Japan Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

    • 8.6 India Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

    • 8.7 South Korea Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast (2022-2028)

    9 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Outlook by Types and Applications to 2022

    • 9.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Oral Medications Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Temozolomide Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Radiosensitizers Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Nitrosoureas Drugs Consumption and Growth Rate (2017-2022)

      • 9.1.5 Global Radiation Therapy Consumption and Growth Rate (2017-2022)

      • 9.1.6 Global Chemotherapy Consumption and Growth Rate (2017-2022)

    • 9.2 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospitals Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Clinics Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Ambulatory Surgical Centers Consumption and Growth Rate (2017-2022)

    10 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Outlook by Types and Applications to 2028

    • 10.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global Oral Medications Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global Temozolomide Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global Radiosensitizers Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.4 Global Nitrosoureas Drugs Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.5 Global Radiation Therapy Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.6 Global Chemotherapy Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Hospitals Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Clinics Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.3 Global Ambulatory Surgical Centers Consumption Forecast and Growth Rate (2022-2028)

    11 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Competitive Analysis

    • 14.1 AngioChem

      • 14.1.1 AngioChem Company Details

      • 14.1.2 AngioChem Recurrent Glioblastoma Multiforme (GBM) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 AngioChem Recurrent Glioblastoma Multiforme (GBM) Treatment Product and Service

    • 14.2 GlaxoSmithKline

      • 14.2.1 GlaxoSmithKline Company Details

      • 14.2.2 GlaxoSmithKline Recurrent Glioblastoma Multiforme (GBM) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 GlaxoSmithKline Recurrent Glioblastoma Multiforme (GBM) Treatment Product and Service

    • 14.3 Roche

      • 14.3.1 Roche Company Details

      • 14.3.2 Roche Recurrent Glioblastoma Multiforme (GBM) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Roche Recurrent Glioblastoma Multiforme (GBM) Treatment Product and Service

    • 14.4 Vascular Biogeneics

      • 14.4.1 Vascular Biogeneics Company Details

      • 14.4.2 Vascular Biogeneics Recurrent Glioblastoma Multiforme (GBM) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 Vascular Biogeneics Recurrent Glioblastoma Multiforme (GBM) Treatment Product and Service

    • 14.5 Astrazeneca

      • 14.5.1 Astrazeneca Company Details

      • 14.5.2 Astrazeneca Recurrent Glioblastoma Multiforme (GBM) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 Astrazeneca Recurrent Glioblastoma Multiforme (GBM) Treatment Product and Service

    • 14.6 Merck

      • 14.6.1 Merck Company Details

      • 14.6.2 Merck Recurrent Glioblastoma Multiforme (GBM) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 Merck Recurrent Glioblastoma Multiforme (GBM) Treatment Product and Service

    • 14.7 Pfizer

      • 14.7.1 Pfizer Company Details

      • 14.7.2 Pfizer Recurrent Glioblastoma Multiforme (GBM) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 Pfizer Recurrent Glioblastoma Multiforme (GBM) Treatment Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Recurrent Glioblastoma Multiforme (GBM) Treatment

    • Figure Recurrent Glioblastoma Multiforme (GBM) Treatment Picture

    • Table Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption by Country (2017-2022)

    • Figure United States Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate (2017-2022)

    • Table Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate (2017-2022)

    • Figure China Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Japan Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate (2017-2022)

    • Figure India Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate (2017-2022)

    • Figure South Korea Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Global Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast by Country (2022-2028)

    • Figure United States Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Recurrent Glioblastoma Multiforme (GBM) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Oral Medications Consumption and Growth Rate (2017-2022)

    • Figure Global Temozolomide Consumption and Growth Rate (2017-2022)

    • Figure Global Radiosensitizers Consumption and Growth Rate (2017-2022)

    • Figure Global Nitrosoureas Drugs Consumption and Growth Rate (2017-2022)

    • Figure Global Radiation Therapy Consumption and Growth Rate (2017-2022)

    • Figure Global Chemotherapy Consumption and Growth Rate (2017-2022)

    • Figure Global Hospitals Consumption and Growth Rate (2017-2022)

    • Figure Global Clinics Consumption and Growth Rate (2017-2022)

    • Figure Global Ambulatory Surgical Centers Consumption and Growth Rate (2017-2022)

    • Figure Global Oral Medications Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Temozolomide Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Radiosensitizers Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Nitrosoureas Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Radiation Therapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Chemotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospitals Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Clinics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Ambulatory Surgical Centers Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Recurrent Glioblastoma Multiforme (GBM) Treatment Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Recurrent Glioblastoma Multiforme (GBM) Treatment Export by Region (Top 5 Countries) (2017-2028)

    • Table AngioChem (Foundation Year, Company Profile and etc.)

    • Table AngioChem Recurrent Glioblastoma Multiforme (GBM) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table AngioChem Recurrent Glioblastoma Multiforme (GBM) Treatment Product and Service

    • Table GlaxoSmithKline (Foundation Year, Company Profile and etc.)

    • Table GlaxoSmithKline Recurrent Glioblastoma Multiforme (GBM) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table GlaxoSmithKline Recurrent Glioblastoma Multiforme (GBM) Treatment Product and Service

    • Table Roche (Foundation Year, Company Profile and etc.)

    • Table Roche Recurrent Glioblastoma Multiforme (GBM) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Roche Recurrent Glioblastoma Multiforme (GBM) Treatment Product and Service

    • Table Vascular Biogeneics (Foundation Year, Company Profile and etc.)

    • Table Vascular Biogeneics Recurrent Glioblastoma Multiforme (GBM) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Vascular Biogeneics Recurrent Glioblastoma Multiforme (GBM) Treatment Product and Service

    • Table Astrazeneca (Foundation Year, Company Profile and etc.)

    • Table Astrazeneca Recurrent Glioblastoma Multiforme (GBM) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Astrazeneca Recurrent Glioblastoma Multiforme (GBM) Treatment Product and Service

    • Table Merck (Foundation Year, Company Profile and etc.)

    • Table Merck Recurrent Glioblastoma Multiforme (GBM) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Merck Recurrent Glioblastoma Multiforme (GBM) Treatment Product and Service

    • Table Pfizer (Foundation Year, Company Profile and etc.)

    • Table Pfizer Recurrent Glioblastoma Multiforme (GBM) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pfizer Recurrent Glioblastoma Multiforme (GBM) Treatment Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US